The polycystic kidney disease drugs market was valued at USD 0.54 Billion in 2025, driven by rising incidence of autosomal dominant polycystic kidney disease across the 8 major markets. The market is expected to grow at a CAGR of 5.90% during the forecast period of 2026-2035, with the values likely to reach USD 0.96 Billion by 2035.
Base Year
Historical Period
Forecast Period
The market growth is fueled by increasing collaborative efforts between pharmaceutical firms and research institutions to spur advanced therapies targeting polycystic kidney disease (PKD) mechanisms.
Increasing incidence of drugs FDA approvals for treating polycystic kidney disease is amongst the major market trends.
Technological innovations in drug development, like high-throughput screenings and personalized medicine are expected to fuel the demand for polycystic kidney disease drugs in the forecast period.
Compound Annual Growth Rate
5.9%
Value in USD Billion
2026-2035
*this image is indicative*
Polycystic kidney disease (PKD) drugs are designed to address the formation of fluid-filled cysts in kidneys, which can lead to kidney dysfunction. The rising prevalence of PKD and the urgent need for effective treatments are driving market growth. The application of advanced technologies such as artificial intelligence and machine learning to generate high efficacy drugs is expected to impact the market landscape significantly. In addition, continued research initiatives, focused on significantly enhancing the scope and growth of the PKD drugs is amongst the major market trends.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increasing Prevalence of Polycystic Kidney Disease (PKD) to Affect the Market Landscape Significantly
Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of polycystic kidney disease, affecting 1 in 500 to 1,000 individuals globally. It is especially exacerbated by diabetes and hypertension. Consequently, rising prevalence of diabetes and obesity, which can be attributed to sedentary lifestyle and lack of an exercise regime can lead to heightened demand for polycystic kidney disease drugs in the coming years.
Surge in FDA Approvals to Meet Rising Polycystic Kidney Disease Drugs Market Demand
In September 2023, the United States FDA approved Eli Lilly’s Jardiance® (empagliflozin) 10 mg tablets for the treatment of chronic kidney disease (CKD). This approval introduced a promising treatment option for over 35 million affected adults, marking a substantial milestone in CKD management. Empagliflozin demonstrated efficacy in slowing CKD progression, as evidenced in the EMPA-KIDNEY phase III trial, and included a notable reduction in hospitalization risks as well.
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
The EMR’s report titled “Polycystic Kidney Disease Drugs Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Leads the Market Share Based on Type
The market segmentation based on disease type is divided into autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD). Out of these, ADPKD emerges as the predominant leader in the polycystic kidney disease drugs market. Its high prevalence among PKD cases secures a significant market share, surpassing its rare counterpart, autosomal recessive polycystic kidney disease (ARPKD).
The market for polycystic kidney disease drugs spans across United States, EU-4 (Germany, France, Italy and Spain), the United Kingdom, Japan and India, with each region significantly contributing to its dynamics. United States stands out as a market leader. Its market value due can be accredited to higher prevalence of PKD in the region. Having a robust regulatory infrastructure also adds notable value. In March 2024, Vertex Pharmaceuticals (VRTX ) received U.S. Food and Drug Administration (FDA) approval for VX- 407, an investigational drug targeting ADPKD. VX-407 is a small molecular corrector, which addresses the underlying cause of ADPKD in patients with specific PKD1 genetic variants.
ADPKD is the most common inherited kidney disease that affects an estimated 250,000 individuals in the United States and Europe combined. Consequently, Europe also holds a significant market share for polycystic kidney disease drugs. In Europe, the presence of affluent research institutions along with a well-established research infrastructure play a critical role in boosting the market value.
They key features of the market report include patent analyses, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
F. Hoffmann-La Roche Ltd, headquartered in Basel, Switzerland, was founded in 1896. The company specializes in pharmaceutical manufacturing and is a leader in the field of cancer drug development and sales. Roche has developed drugs and diagnostics for various disease, including PKD-1 inhibitors. Some of the drugs include Mycophenolate Mofetil (Cellcept), and Valganciclovir (Valcyte).
Galapagos NV, founded in 1999 as a joint venture between Crucell and Tibotec, is headquartered in Mechelen, Belgium. The company specializes in pharmaceutical research and is developing GLPG2737, a CFTR1 inhibitor to treat polycystic kidney disease (ADPKD).
Johnson & Johnson Services, Inc. was established in 1886 in New Brunswick. The company is developing JNJ-0237, an oral medication to treat ADPKD.
Merck and Co. Inc. was founded in 1891, in New York. The company is amongst the leading companies in pharmaceutical development and boasts an elaborate drugs portfolio for a variety of diseases including polycystic kidney disease.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies in the market include AbbVie Inc., Apotex Inc., Amgen Inc., Otsuka Holdings Co. Ltd., Palladio Biosciences Inc., Regulus Therapeutics, Sanofi SA, XORTX Therapeutics Inc., Novartis AG, Teva Pharmaceutical Industries Ltd, and Bayer AG.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Upto 15% Off
USD
$5499 $4949
$3299 $2969
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share